TranspoCART19

Phase I/IIa multicentre phase I/IIa study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beauty family transposons to express a chimeric antigenic receptor with anti-CD19 specificity conjugated to the 4-1BB co-stimulatory and signal-transduction region CD3z and huEGFRt (TranspoCART19) in patients with relapsed or refractory B-cell lymphoma.

Single-center phase I/IIa study of infusion of autologous peripheral blood T cells expanded and genetically modified by Sleeping Beauty family transposons to express a chimeric antigen receptor with anti-CD19 specificity conjugated with the 4-1BB costimulatory region and CD3z and huEGFRt signal transmission (TranspoCART19) in patients with CD19+ acute lymphoblastic leukemia resistant or refractory to treatment